Antibody-oligonucleotide conjugates (AOCs) are a novel class of synthetic chimeric biomolecules that has been continually gaining traction in different fields of modern biotechnology. Creative Biolabs focuses on developing this new class of oligonucleotide conjugates to overcome the current limitations of oligonucleotide (ON) therapies for a wide range of serious diseases.